Novo Nordisk’s Two-Pronged Catalyst: An Analyst Upgrade and a €69 Million Research Bet
21.06.2026 - 17:55:40 | boerse-global.de
Novo Nordisk closed the week with a 3.21% gain, pushing its shares to €38.90 on Friday. The rally was driven by two distinct forces: a bullish analyst call from Nordea and a new European research initiative from the Novo Nordisk Foundation. After months of heavy selling that has left the stock down roughly 13% year-to-date and more than 40% below its 52-week high of €65.20, the move offered a rare moment of relief for investors.
Nordea upgraded the stock from Hold to Buy, setting a price target of 350 Danish kroner. The bank’s optimism centers on the oral version of Wegovy, which has racked up over three million prescriptions in just five months since its U.S. launch. Weekly prescriptions have now surpassed 200,000, making it the most successful GLP-1 launch by volume on record. Nordea projects the pill alone could generate around 18 billion kroner in sales by 2026 — well above the consensus estimate of 11 billion kroner. Berenberg also raised its target to 325 kroner, though Deutsche Bank held firm at Hold, reflecting lingering caution.
Alongside the analyst upgrade, the Novo Nordisk Foundation unveiled “CardioMetabolic Bridge,” a six-year research program investing up to €60.2 million (roughly $69 million) into academic projects targeting obesity, Type 2 diabetes, and related metabolic disorders. The first lab opens this month in London, with additional sites planned in Germany and Italy. Around 30 projects will be funded. While the foundation operates independently of the publicly traded company, the initiative ensures Novo Nordisk maintains a long-term pipeline of novel drug candidates.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Distribution is also expanding. A recently announced partnership with telehealth platform Hims & Hers will give U.S. consumers access to Ozempic and both the injectable and oral forms of Wegovy at standard telemedicine pricing. The weight-management membership starts at $39 for the first month and $149 thereafter, broadening reach beyond traditional pharmacy channels. Barclays responded by lifting its price target on Hims & Hers to $39, citing a 35% year-over-year jump in website traffic and a 16% month-over-month rise in transaction volumes.
Meanwhile, Novo Nordisk’s share buyback program continues in the background. As of mid-June, the company had repurchased nearly 20 million B-shares at a cost of 5.27 billion kroner. That discretionary support, however, has not been enough to offset the broader downdraft: the stock still trades well below its 52-week high, and the first-quarter earnings update for 2026 actually guided for a 4% to 12% decline in sales and profit at constant exchange rates.
The rapid adoption of oral Wegovy is already reshaping the competitive landscape. Novo Nordisk management reportedly sees oral therapies capturing 40% to 60% of the GLP-1 market in the medium term — a shift that threatens suppliers of injection pens. Gerresheimer, a key manufacturer of pens for Ozempic, had counted on annual revenues of €350 million from that business. The growing preference for pills undermines that forecast, creating a stark divergence: JPMorgan rates Gerresheimer Overweight with a €46 target, while UBS recommends selling at €12.90.
Investors will now look ahead to the second-quarter results due on August 5. The focus will be on the global rollout of the Wegovy pill beyond the U.S. — a process that has already secured marketing authorization in the United Arab Emirates. The pace of that international expansion, along with the looming Medicare Part D coverage of obesity drugs starting July 1, will set the tone for the stock in the months ahead. For Novo Nordisk, the week’s twin catalysts have bought some breathing room, but the real test lies in whether prescription momentum and pipeline investment can translate into sustained earnings growth.
Ad
Novo Nordisk Stock: New Analysis - 21 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
